AP
ICPT

AHL Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

AHL Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,755
Closed -$289K – 1215
2016
Q3 		$289K Buy
+1,755
New +$277K 0.01% 987

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

AHL Partners's ICPT Position: Q4 2016 in Review

AHL Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2016, closing a stake of 1,755 shares — an estimated $289K sold.

AHL Partners first reported a position in ICPT in Q3 2016 and held it in 1 quarter. The position peaked at $289K in Q3 2016. 159 funds tracked by Wall St. Rank hold ICPT as of Q4 2016.

  • AHL Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • AHL Partners sold 1,755 Intercept Pharmaceuticals, Inc. shares in Q4 2016, an estimated $289K.
  • AHL Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • AHL Partners's Intercept Pharmaceuticals, Inc. position peaked at $289K in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2016.

Based on AHL Partners's 13F filing for Q4 2016, filed 14 Feb 2017.